Dermatologic Toxicities Associated With Novel Pan-RAS/RAF Inhibitors.
Lin J He, Shaymaa Hegazy, Phyu P Aung et al.
✦ AI-curated · Sources linked
From the abstract
The mitogen-activated protein kinase (MAPK) pathway plays a key role in cell-cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan-RAS (RMC-6236) and pan-RAF (LXH254/naporafenib) inhibitors are emerging.
Reported results
Associated DTs were identified in eight patients treated with either pan-RAS (n = 4) or pan-RAF (n = 4) plus MEK/ERK inhibitors for RAS mutated tumors (colorectal, lung, pancreatic, thyroid, melanoma). The patients ranged from 37 to 72 years of age. Five patients had initial clinical presentation of an acneiform eruption complicated by ulceration, flaccid vesicles, or diffuse exfoliative erythroderma.
Authors' conclusions
Treatment with novel pan-RAS/RAF inhibitors exhibits a spectrum of DTs that exhibit some overlap with small molecule inhibitors that target the MAPK pathway.